in the end subjective value judgements. Consequently different researchers can come to rather different summaries regarding the relative profitability of a set of rivaling pharmaceutical products (to see it Pauly, chapter 10 and Drummond, chapter 11). The sources of such differences can be put bare, only if all these studies are opened for full, external to balance regarding the raw data, which enter into the studies, to the method teachings, which are used, in order to convert the raw data for analysis, and to the analyses themselves (Reinhardt 1997). , Most objective economicalness, the question studies the many judgements issued, which must be formed by the researchers even in the best one develops, whom she should lead, around it really useful to form for the market of the pharmaceutical products. If those studies are led or financed by from third the source payers, they are governments, or private insurers, are them suspectedbypharmaceutical producer, physicians and patients rave immediately, which is perhaps affected in favorof the cost savings, to the expensive quality. But, if these studies of the pharmaceutical producers, since they are now are usually led or financed, are them under from third source payers (Millenson 2004) and under the public similarly probably defectively. Which therefore is necessary are research institutes, which are for taxation independent of each side of the pharmaceutical market and therefore too also not side obligated. In „an information infrastructure for the pharmaceutical market, “this author suggested such an approach for the United States, although it would be applicable to each possible country (Reinhardt 2004). Or some private, non-profit Phamaco economic research institutes (PERIs) were preferably formed permanently by law and generous initial equipment granted, which we said of the government to 1% a tax on all pharmaceutical retail trade sale in or two years were financed. These equipments could be supplemented by the time or by the time at the beginning or been enough generous not to need such enrichments. Like private universities in the United States, the PERIs would invest its equipments in varied briefcases of the financial active. The return of these investments and of possibly annual Take downs the equipments themselves, became a current sentence research studies financiers, who were led by high calibers, to a high degree - respected pharmaco economic researchers found either at the PERIs themselves or in the academic institutes, which work under contract of the PERIs. These studies will are constantly by everyone regarding the raw data and the method teachings completely überprufbar and would cover by the researchers, who were engaged by pharmaceutical industry. The PERIs would also supervise the achievement of the drugs after product introduction and would evaluate new therapeutic applications, which emerge after product introduction. The research discoveries, which were produced by the PERIs, were treated as pure Gemeingut+E896, therefore it that they were announced to be on a web site and world-wide present for everyone, meant free of charge. The mechanism of the relative profitability of the rivaling pharmaceutical products raises extraordinary methodologische problems, as greatly well-being descriptive in the Bible for such studies, Drummond et al. Methods for the economic evaluation of the health care programs (2005). „The costs “, which are used in such evaluations, can be analyzed narrowly, in order to be only those the insurer or the insurer and the patients, or all social costs to cover including very far those by the family members, by the employers and by others in the society to be carried (e.g., infection). Use in the Kostengünstigkeitstudien is usually measured by physical Gesundheitstatus announcements, stored like added life years or changes in the blood pressure, but they must be adjusted to the quality of life, which release in sequence a landlord of the additional methodologischen challenges and, Given the many judgments that must fuel element larva by researchers into even the best, most objective cost effectiveness studies, the question arises who should conduct them, ton make them truly useful for the market OF pharmaceutical products. If those studies of acres conducted or funded by third party payers, fuel element they governments or private insurers, they wants immediately fuel element suspectedbypharmaceutical producer, physicians, and patients raves biased in favorof cost savings, possibly RK the expensive OF quality. But if thesis of studies of acres conducted or funded by pharmaceutical producer, as now they typically acres, they acres similarly suspect among third party payers (Millenson 2004) and among the general public. What is needed, therefore, acres research institute that acres fiscally independent OF more either side OF the pharmaceutical market and, therefore, beholden tons more neither side. Into “Pharmaceutical Market at information Infrastructure for,” this author proposed look for on approach for the United States, although it would fuel element applicable ton any country (Reinhardt 2004). One or preferably several private, nonprofit Phamaco Economic Research of institute (PERIs) would fuel element established permanently by law and granted A generous initially endowment financed by government, say, A 1% tax on all pharmaceutical retail sales over one or two years. Thesis endowments could fuel element replenished from time or time or fuel element generous enough RK the outset emergency ton need look for replenishments. Like private universities into the United States, the PERIs would invest their endowments in diversified portfolios OF financial assets. The returns from thesis investments, and perhaps annual take downs OF the endowments themselves, would finance on ongoing set OF research studies conducted by high more caliber, highly respected pharmaco economic researchers located either RK the PERIs of themselves or in academic institution working more under contract from the PERIs. Thesis of studies would fuel element fully auditable, RK of all times, by anyone as tons raw DATA and methodology, including by researchers engaged by the pharmaceutical industry. The PERIs thus would monitor the performance OF drugs after launch and evaluate new therapeutic applications emerging after launch. The research findings produced by the PERIs would fuel element treated as A pure public good, which means that they would fuel element posted on A web site and fuel element available worldwide ton anyone, free OF load. The establishment OF the relative cost effectiveness OF rival pharmaceutical products pos extraordinary methodological problem, as is superbly wave described into the bible for look for studies, Drummond et al. 's Methods for the Economic evaluation OF Health Care of program (2005). The “costs” used in look for evaluation CAN fuel element narrowly construed tons of fuel element only those OF insurers or OF insurers and patients, or very widely ton include all social costs, including those founts by family members, employers, and others in society (e.g., though contagion). Benefits into cost effectiveness studies typically acres measured by physical health status of indicator, look for as added life years saved or CHANGEs into blood pressure, but they must fuel element adjusted for the quality OF life, which and challenges in turn of trigger A host OF additional methodological,